A Phase 2 interventional study of BGB-45035 and Placebo in Rheumatoid Arthritis, sponsored by BeiGene. Terminated at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 160th largest by enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 34 in phase 2, and was the 214th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in China, United States, Belgium and 8 more countries
Ages 18–65
Peking University People's Hospital · Sites in China
Ages 18+
Jacobio Pharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 46 · Phase 3 52 · Phase 4 28
First in 2003; this study’s year is marked. 35 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 134 across the 217 interventional studies, 287 across the 32 observational. Of the 115 that completed or were terminated, 28 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 249 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06887127Phase 3Hangzhou Highlightll Pharmaceutical Co., LtdA Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | 2026-12-31 |
| NCT07408024Toll Biotech Co. Ltd. (Beijing)Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis | 2026-12 |
| NCT07045896Peking University People's HospitalFucoidan in the Treatment of Active Rheumatoid Arthritis | 2026-12 |
| NCT06945666Jie ChangA Study of Iguratimod in Combination With Tofacitinib in RA Patients | 2027-01-31 |
| NCT07491016Zhejiang Provincial People's HospitalEfficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis | 2027-03-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy of BGB-45035 in adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying antirheumatic drugs (bDMARDs)/targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive BGB-45035 orally for up to 12 weeks
Drug: BGB-45035
Participants will receive placebo orally for up to 12 weeks
Drug: Placebo
Administered orally
Administered orally
Change from baseline in Disease Activity Score - C-reactive protein (DAS28-CRP) at Week 12
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), high-sensitivity C-reactive protein (hsCRP in mg/L), and Patient's Global Assessment of Arthritis Pain (measured on a Visual Analog Scale \[VAS\] from 0 \[no pain\] to 100 \[worst possible pain\]). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A score greater than 5.1 indicates high disease activity, a score between 3.2 and 5.1 indicates moderate disease activity, a score between 2.6 and 3.2 indicates low disease activity, and a score less than 2.6 indicates the participant is in remission.
Time frame: Baseline and Week 12
Percentage of participants with a 20% improvement in American College of Rheumatology Criteria (ACR20)
The ACR20 is defined as at least 20% improvement in the ACR core set values as defined below. Participants must meet 3 conditions for improvement from Baseline: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of participants with a 50% improvement in American College of Rheumatology Criteria (ACR50)
The ACR50 is defined as at least 50% improvement in the ACR core set values as defined below. Participants must meet 3 conditions for improvement from Baseline: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of participants with a 70% improvement in American College of Rheumatology Criteria (ACR70)
The ACR70 is defined as at least 70% improvement in the ACR core set values as defined below. Participants must meet 3 conditions for improvement from Baseline: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Change from Baseline in Tender Joint Count 68 (TJC 68)
The TJC 68 is an assessment of tenderness or pain in 68 joints. Sixty-eight joints will be assessed for tenderness/pain by an independent, blinded assessor. The response to pressure/motion on each joint is assessed using the following scale: Present/Absent/Not Done/Not Applicable. A lower score indicates there is less pain or tenderness present, while a higher score indicates more pain or tenderness is present.
Time frame: Baseline up to Week 12
Change from baseline in Swollen Joint Count 66 (SJC 66)
The SJC 66 is an assessment of swelling in 66 joints. Sixty-six joints will be assessed for swelling by an independent, blinded assessor. The swelling present in each joint is assessed using the following scale: Present/Absent/Not Done/Not Applicable. A lower score indicates there is less swelling present, while a higher score indicates more swelling is present.
Time frame: Baseline up to Week 12
Change from baseline in physician's global assessment of disease activity (PhGADA_VAS)
The PhGADA\_VAS is a single item that asks the physician to assess the participant's current disease activity on a 0- to 100-mm visual analog scale (VAS), with anchors of 0 = "no disease activity" and 100 = "extremely active disease."
Time frame: Baseline up to Week 12
Change from baseline in Simplified Disease Activity Index (SDAI) score
The simplified disease activity index (SDAI) is a composite measure that sums the total number of: * 28 tender joint counts, * 28 swollen joint counts, * Patient's Global Assessment of Disease Activity measured on a VAS from 0 to 10 where 0= lowest disease activity and 10 = highest; * Physician's Global Assessment of Disease Activity measured on a VAS from 0 to 10, where 0 = lowest disease activity and 10 = highest, and * C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity.
Time frame: Baseline up to Week 12
Change from baseline in Clinical Disease Activity Index (CDAI) score
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: * 28 tender joint count (TJC), * 28 swollen joint count (SJC), * Patient's Global Assessment of Disease Activity measured on a VAS from 0 to 10 where 0 = lowest disease activity and 10 = highest; * Physician's Global Assessment of Disease Activity (measured on a VAS from 0 to 10 where 0 = lowest disease activity and 10 = highest). The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity.
Time frame: Baseline up to Week 12
Change from baseline of participant's global assessment of disease activity (PaGADA_VAS)
The PaGADA\_VAS is a single item that asks the patient to rate the current severity of their disease activity on a 0- to 100-mm VAS, with anchors of 0 = "no disease activity" and 100 = "extremely active disease."
Time frame: Baseline up to Week 12
Change from baseline of Participant's global assessment of arthritis pain (VAS)
The Participants's global assessment of arthritis pain (VAS) is a single item that asks the patient to rate the current severity of their pain in relation to their RA on a 0- to 100-mm VAS, with anchors of "no pain" and "worst possible pain."
Time frame: Baseline up to Week 12
Change from baseline of Participant's assessment of physical function as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI)
The HAQ-DI is a patient-reported questionnaire that is commonly used in RA to measure disease-associated disability (assessment of physical function). Participants answer 24 questions using a scale from 0 to 3 to score difficulty when performing daily activities over the past week (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). Scores on each task are averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three represents very severe, high-dependency disability.
Time frame: Baseline up to Week 12
Number of participants with adverse events (AEs)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including findings from laboratory tests
Time frame: Up to approximately 4 months
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in May 2026, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.